Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01946152 · OUTCOME

Number of Participants With Progression-free Survival

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2021-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 6 years

Analysis population: Data provided for the Participants who received MTD

Groups in this outcome

Maximum Tolerated Dosage (MTD)

5 mg of Pomalidomide Daily days 1 - 21. 40 mg Dexamethasone On days 1, 8. 15, 22. 4mcg/kg of Zarxio (G-CSF) Days 22- 28.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Maximum Tolerated Dosage (MTD)8

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Maximum Tolerated Dosage (MTD)3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
groups
  1. description
    5 mg of Pomalidomide Daily days 1 - 21. 40 mg Dexamethasone On days 1, 8. 15, 22. 4mcg/kg of Zarxio (G-CSF) Days 22- 28.
    id
    OG000
    title
    Maximum Tolerated Dosage (MTD)
param Type
COUNT_OF_PARTICIPANTS
population Description
Data provided for the Participants who received MTD
reporting Status
POSTED
time Frame
Up to 6 years
title
Number of Participants With Progression-free Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice